2025 Desert Liver Conference Video Recordings
The 2025 Desert Liver Conference Recap features recordings of key discussions and presentations, offering valuable insights into the latest advancements in hepatology.
Esteemed medical professionals from across the country gathered to share their expertise on innovative treatments and emerging research trends. These videos capture essential knowledge and perspectives from our distinguished speakers.
Friday, March 7 - Day 1
Opening Remarks – Overview of the NIT Landscape
NITs and Digital Pathology Industry Presentation – Echosens/e-Scopics/Sonic Incytes/ Mindray-Aegle/ Fibronostics/ Cima/ HistoIndex
NITs & Digital Pathology Industry Demonstrations
Break
Opening Remarks & Introductions
Identifying Patients in Primary Care & Diabetes Clinics that need Referrals to Specialists
Selecting Patients for Pharmacological Treatments & Specialty Clinics
Monitoring Response to Treatment with NITs
Putting Everything Together – Real World Cases
Saturday, March 8 - Day 2
Video 1
Opening Remarks
Session 1 – Viral Hepatitis
- An update on HBV Treatment: Is the cure in sight?
- Innovations in HCV Elimination: The Global Perspective
- Innovations in HCV Elimination: The Local Perspective
- Panel Discussion and Q&A
Break
Session 2 – MASLD & MASH
- Treatment with Resmetirom: Who should be treated and how to monitor response?
- Treatment with GLP1 agonists and dual agonists: What are the liver benefits?
- The future of MASH Management: Looking into the Crystal Ball
- Practical SLD Cases & Patients’ Perspective
– Combination Therapy Case
– MetALD Management Case
– MASH Cirrhosis Management Case - Panel Discussion and Q&A
Video 2
Session 3 – Cholestasis
- Update on PBC & Genetic Liver Diseases including Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
- An Update on other Causes of Cholestasis from PSC to Genetic Cholestasis
- DILI Overview for Practitioners: Case Based Discussion
- Oral Presentation #1 of Original Research
- Panel Discussion and Q&A
Break
Session 4 – Cirrhosis & Liver Cancer
- Preventing Complications in Cirrhosis
- New and Old Treatments for Alcohol-Associated Hepatitis
- Updates in HCC Screening, Prevention & Treatment
- Cirrhosis and HCC Cases
– Spontaneous Bacterial Peritonitis (SBP) Prophylaxis
– HCC Treatment: Role for Combination - Oral Presentation #2 of Original Research
- Panel Discussion and Q&A
Closing Remarks
The incidence of metabolic dysfunction-associated steatohepatitis (MASH) is growing rapidly. Patients with or at risk for MASH are underdiagnosed, and thus they may not be benefiting from newly approved liver-directed therapies that can alter the disease course. In this case-based symposium, compete against your colleagues as you trek across desert landscapes in search of critical information about noninvasive testing for MASH, risk stratification, treatment selection and monitoring, and other important topics. The race is on to explore MASH treatments and search for “best practices” that you can implement in your own MASH care pathways. Join us and test your knowledge in this Dash for Mash!
Enduring URL: www.medscape.org/sympo/mash-desert-2025-enduring